1. Anti-infection
  2. Influenza Virus
  3. PB2-IN-2

PB2-IN-2 是一种口服有效的 PB2 抑制剂,其 RNP 抑制活性 (IC50) 为 0.2 nM,细胞水平复制抑制活性 (LRA EC50) 为 0.8 nM,细胞病变效应抑制活性 (CPE EC50) 为 0.1 nM。。PB2-IN-2 对一组甲型流感病毒株 (包括 H1N1pdm09、Lyon/1337/2007/H1N1、Tex12-Like/H3N2、PR/8/34/H1N1、WSN/1933/H1N1 及 rPR8(H1N1)/H7N9) 展现出纳摩尔水平的广谱抗病毒效力 (EC50 分别为 1.5、3.6、3.7、13.8、2.9 和 9.8 nM,且 CC50 值均大于 2 μM)。PB2-IN-2 拥有优异的代谢稳定性和药代动力学特征。PB2-IN-2 可用于抗流感研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

PB2-IN-2

PB2-IN-2 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

PB2-IN-2 is an orally active PB2 inhibitor with RNA-dependent RNA Polymerase (RNP) IC50 = 0.2 nM, LRA (Ligand Receptor Assay) EC50 = 0.8 nM, Cytopathic Effect (CPE) EC50 = 0.1 nM. PB2-IN-2 exhibits broad-spectrum, nanomolar antiviral potency against a panel of influenza A strains (including H1N1pdm09, Lyon/1337/2007/H1N1, Tex12-Like/H3N2, PR/8/34/H1N1, WSN/1933/H1N1, rPR8(H1N1)/H7N9 with EC50 = 1.5, 3.6, 3.7, 13.8, 2.9 and 9.8 nM and all the CC50 values > 2 μM. PB2-IN-2 possesses an excellent pharmacokinetic profile and metabolic stability. PB2-IN-2 can be used for anti-influenza research[1].

体外研究
(In Vitro)

PB2-IN-2 (compound 3) 具有较低的亲脂性 (LogD 值为 1.27)[1]
PB2-IN-2 在 A549 肺细胞中对一系列野生型和实验室适应的甲型流感病毒 (包括 H1N1pdm09、Lyon/1337/2007/H1N1、Tex12-Like/H3N2、PR/8/34/H1N1、WSN/1933/H1N1 以及 rPR8(H1N1)/H7N9 病毒株) 表现出卓越的抑制活性,其 EC50 分别为 1.5、3.6、3.7、13.8、2.9 和 9.8 nM,且所有 IC50 值均大于 2 μM,并且显示出良好的安全窗口[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

PB2-IN-2 (compound 3) 在小鼠体内表现出较高的游离血浆分数 (1.2%)[1]
PB2-IN-2 (0.05-1 mg/kg,口服给药,每日两次,持续 5 天) 在甲型流感病毒小鼠感染模型中,具有低有效剂量、平缓的疗效-剂量关系及宽治疗窗等特征[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A/Puerto Rico/8/34 (3 × 105 TCID50, i.n.) induced-male BALB/c mice[1]
Dosage: 0.05, 0.1, 0.3, and 1 mg/kg
Administration: p.o., twice daily for 5 days
Result: Provided 100% protection at a minimum dose of 0.3 mg/kg.
Achieved full protection maintaining in vitro EC50 coverage for more than 18 h.
Lost peak body weight at 10% by day 7 and recovered by day 14 at 0.3 mg/kg.
分子量

412.39

Formula

C20H18F2N6O2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
PB2-IN-2
目录号:
HY-180525
需求量: